靶向HMGB1治疗中性粒细胞性哮喘的研究进展

Progress in targeting HMGB1 for the treatment of neutrophilic asthma

高迁移率族蛋白1(HMGB1)是一种高度保守的核蛋白,在细胞核中参与转录、复制、DNA修复和核小体组装。细胞外HMGB1作为报警蛋白参与各种炎症反应和自身免疫。中性粒细胞性哮喘(NA)是由非2型炎症因子驱动所引起的气道中性粒细胞性炎症,目前缺乏有效的治疗方法。研究表明,HMGB1在中性粒细胞性哮喘诊断和治疗中具有一定的临床价值,可能成为潜在的中性粒细胞哮喘的治疗药物。本文综述了HMGB1的结构与功能、其与受体的相互作用以及在中性粒细胞哮喘靶向治疗中的研究进展,为寻找新的有效的中性粒细胞哮喘治疗药物提供帮助。

High mobility group box-1 protein(HMGB1)is a highly conserved nuclear protein involved in transcription,replication,DNA repair,and nucleosome assembly in the nucleus.Extracellular HMGB 1 acts as an alarm protein involved in various inflammatory responses and autoimmunity.Neutrophilic asthma(NA)is a neutrophilic inflammation of the airway driven by non-type 2 inflammatory factors,but effective treatments are currently lacking.Studies have shown that HMGB 1 has some clinical values in the diagnosis and treatment of neutrophilic asthma and may be a potential therapeutic agent for neutrophilic asthma.This review summarizes the structure and function of HMGB1,its interaction with receptor,and advances in the targeted therapy of neutrophilic asthma,to facilitate the research for new effective therapeutic agents for neutrophilic asthma.